Nobel

What Nobel does

Nobel İlaç San. ve Tic. A.Ş. is a privately held Turkish pharmaceutical company founded in 1964 and wholly owned by Ulkar Holding, operating with 100% domestic Turkish capital. It manufactures and sells a broad portfolio of generic pharmaceuticals, biosimilars, active pharmaceutical ingredients (APIs) and biotechnological drug products, including Turkey's first biosimilar erythropoietin (launched 2010) and Tylol Hot, a flagship consumer cold/flu brand registered in 1998. The company runs five manufacturing facilities — Düzce (main facility, ~40,000 m² closed area), Gebze MARTEK (biotechnology, 2x1000L reactor capacity), Çerkezköy/Ulkar Kimya (APIs and coated micropellets) in Turkey, plus Nobel AFF in Almaty, Kazakhstan and Nobel Pharmsanoat in Tashkent, Uzbekistan — together producing over 360 SKUs across roughly 143 molecules, with annual capacity of 750 million tablets at Nobel AFF and 10 million boxes at Pharmsanoat. Approximately 3,000 employees support operations across 20 countries with owned direct-sales organizations and exports to roughly 50 countries.

The business model is primarily horizontal generic-pharma sales into government healthcare systems, hospital networks and retail pharmacies across CIS, Balkans, Central Asia, Caucasus and select European markets, supported by owned distribution rather than third-party channels. R&D is conducted at three centers (Düzce Pharmaceutical R&D, MARTEK Biotechnology, Ulkar Kimya), with 95% of the Turkish product portfolio developed in-house. Notable technical milestones include the first Turkish-EU-GMP certifications (2009), the first biosimilar erythropoietin launch in Turkey (2010), and the KAMAG-1007 BIOSIM-1 state-supported biosimilar program (2015, $10M TÜBİTAK support) plus an original biotechnological molecule development partnership with Bilkent University (2016). Capital deployment includes $40M (2002) and $30M (2015) into Nobel AFF, with a further $50M planned for biotech, and $25M from IFC (2017) for the biotechnology facility — alongside TÜBİTAK and TURQUALITY program support. Pricing is not publicly disclosed; the company monetizes through direct B2B sales to pharmacies, hospitals and government procurement channels rather than digital or consumer-direct channels.

Name

Nobel

Legal name

Nobel İlaç Sanayi ve Ticaret Anonim Şirketi (A.Ş.)

Website

https://nobel.uz

Company type

Private

Founded year

1964

Operating status

Operating

Headcount range

11–50 employees

Short description

Nobel İlaç is a privately held Turkish pharmaceutical manufacturer founded in 1964, producing generics, biosimilars, APIs and biotech drugs across five facilities in Turkey, Kazakhstan and Uzbekistan, and serving pharmacies, hospitals and government healthcare systems in 20 countries with owned organizations plus 50 export markets.

Ownership category

akta.pro rank

Product category

Generic Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Generic Hospital & Institutional Products (HLAIABAL)

akta.pro secondary industry

Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)

Keywords

• Generic pharmaceuticals
• Biotechnology drug development
• Biosimilar manufacturing
• Active pharmaceutical ingredients
• Pharmaceutical contract manufacturing

Headquarters

HQ city

Tashkent

HQ country

Uzbekistan

HQ region

Asia

Offices8 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Product Sales: Nobel generates revenue through manufacturing and selling pharmaceutical products including drugs, supplements, and medical products. The company exports to 50 countries and conducts direct sales through own organizations in 20 countries.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels3 records

Core offering

Nobel manufactures and sells a broad portfolio of generic pharmaceutical drug products, biotechnological drugs (including biosimilars such as erythropoietin), active pharmaceutical ingredients, and coated micropellets. Its products are distributed to pharmacies, hospitals, and healthcare providers across roughly 50 export countries, with the company operating its own sales organizations in 20 countries and five manufacturing facilities in Turkey, Kazakhstan, and Uzbekistan.

Product overview

Nobel is a Turkish pharmaceutical company founded in 1964 with 100% domestic capital, operating globally with 5 manufacturing facilities (3 in Turkey, 1 in Kazakhstan, 1 in Uzbekistan) and own organizations in 20 countries. The company produces a comprehensive portfolio of generic pharmaceutical products including Albebezol (albendazole), Aldobel (sildenafil), Alzanser (olanzapine), Anzibel (chlorhexidine lozenges), Antagrix (clopidogrel), Aprid (amoxicillin/clavulanic acid), Afil (alfuzosin), Tylol Hot, and Neotylol for cold/flu treatment. Nobel exports to approximately 50 countries. Their manufacturing operations include Nobel Pharmsanoat in Uzbekistan (10 million boxes/year capacity, 110 products), Nobel AFF in Kazakhstan (750 million tablets/year, 250 products), Gebze MARTEK for biotechnological drugs (2x1000L reactors), Düzce Manufacturing Facility for conventional dosage forms, and Ulkar Kimya for active pharmaceutical ingredients. Nobel also publishes Nobel Medicus, a peer-reviewed medical journal.

Differentiator

Problem solved

Functional benefit

Brands

• Nobel Pharma Schweiz AG: Subsidiary handling pharmaceutical operations in Switzerland
• Generinobel
• Nobelfarma
• Plantafarma
• Nobel Medicus

Products and services

• Tylol Hot

Quantifiable outcome

• First biosimilar erythropoietin product launched in Turkey (2010)
• +2 more outcomes

Named customers2 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Five partnerships are on record, tiered core and minor.

• Bilkent UniversitycoreStrategic or Co-development Partner · 1 January 2016Partnership with Bilkent University for recombinant bi-mAb project - Turkey's first biotechnological original molecule development project, started in 2016 with TÜBİTAK support.
• Institute of Herbal Substances Chemistry of Uzbekistan Academy of SciencesminorStrategic or Co-development PartnerNobel Pharmsanoat cooperates with the Institute for development of pharmaceutical products based on local officinal plants of Uzbekistan. 3 of 5 products manufactured with domestic active substances are exported abroad.
• Ulkar HoldingcoreOthersNobel Pharmaceuticals is part of Ulkar Holding. Ulkar Holding encompasses Nobel İlaç and other companies including Ulkar Kimya. Nobel AFF and Nobel Pharmsanoat are subsidiaries under Ulkar Holding.
• Turkish Ministry of HealthcoreStrategic or Co-development PartnerUlkar Kimya holds EU GMP certificate awarded by Turkish Republic Ministry of Health (PIC member) as well as BfArM Germany certification.
• TURQUALITY ProgramcoreStrategic or Co-development PartnerNobel Pharmaceuticals was included in the brand support program (TURQUALITY) within the framework of the state-supported branding program in 2014.

Scale indicators10 records

Recent moves14 records

Expansion highlights5 records

Direct peers

• Aurobindo Pharma: Indian generic pharmaceutical manufacturer with global distribution and growing biosimilar portfolio. Comparable in combining generic manufacturing scale with international expansion into emerging markets, including CIS regions where Nobel also operates.
• Dr. Reddy's Laboratories: Indian generic and biosimilar manufacturer with significant emerging-markets footprint and growing biosimilar pipeline. Comparable to Nobel in combining generic production with biosimilar capabilities, though at much larger scale.
• KRKA: Slovenian generic pharmaceutical manufacturer with strong CIS, Central/Eastern European, and Russian market presence. Similar size and international expansion strategy to Nobel, with comparable generic-portfolio and own-distribution approach.
• Eczacıbaşı Pharmaceuticals: Turkish conglomerate-affiliated pharmaceutical manufacturer, also part of a diversified holding group (similar to Nobel's Ulkar Holding structure). Competes with Nobel in Turkey and selected international markets with generic and branded pharmaceutical products.
• Stada Arzneimittel: European-focused generic pharmaceutical company with strong presence in CIS and Eastern European markets - highly comparable to Nobel's geographic focus. Both emphasize biosimilar/generic portfolios with multi-country own-distribution models.
• Hikma Pharmaceuticals: Jordan-headquartered generic pharmaceutical company with strong MENA and emerging-markets presence. Comparable business model to Nobel's own-distribution approach across multiple geographies, with similar product portfolio breadth.
• Abdi İbrahim: Turkey's largest pharmaceutical company and direct domestic peer. Both are Turkish-headquartered generic pharmaceutical manufacturers with international operations and own distribution organizations across multiple countries, competing head-to-head in CIS, European, and emerging markets.

Broad incumbents

• Sandoz: Global leader in generic pharmaceuticals and biosimilars (Novartis spin-off). Competes with Nobel in generics and biosimilars globally; much larger scale and broader geographic footprint make Sandoz a broad incumbent rather than a direct niche competitor.
• Teva Pharmaceutical Industries: World's largest generic pharmaceutical manufacturer with extensive biosimilar pipeline. Competes with Nobel in global generics and biosimilars but operates at vastly larger scale and broader geographic scope as a broad incumbent.

Regional players

• Polpharma: Poland's largest pharmaceutical manufacturer with focus on generics, APIs, and biosimilars. Comparable vertically-integrated model (own API production) and Central/Eastern European market focus, though primarily Poland-centric rather than Turkey-based.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/channel/UCbhCEyy00qB1h--2oLOAMNw
• Facebookfacebook.com/nobelpharmsanoat.uz
• Instagraminstagram.com/nobel.uz

Compliance13 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries9 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nobel